№ files_lp_3_process_7_094192
File format: docx
Character count: 3078
File size: 40 KB
School emergency health plan outlining medical background, warning signs, crisis symptoms, response procedures, consent provisions, and information-sharing authorization for a student diagnosed with Sickle Cell Anemia within a county school system.
Year:
Current school year
Revision date:
January 2020
Organization:
Duplin County School System
Department:
Student Health Services
Document type:
School emergency health plan
Medical condition:
Sickle Cell Anemia Disorder
Intended location of use:
School setting
Target individuals:
Student with Sickle Cell Anemia, school staff, parents/guardians
Required signatures:
Parent/Guardian, School Nurse
Parental consent included:
Yes
Medical information release authorization:
Included
Distribution:
Teachers, office personnel, bus driver, emergency responders
Filing instruction:
File original in IHR; copies to appropriate staff and Emergency Action Plan Notebook
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / city:
USA
Topic:
Iron Deficiency Anemia Treatment
Document type:
Medical guideline
Organization / institution:
Centers for Disease Control and Prevention (CDC)
Author:
Not specified
Target audience:
Pregnant individuals, healthcare professionals
Period of validity:
Ongoing
Date of approval:
2023
Date of revisions:
15 February 2021, 31 March 2022, April 2023
Context:
This document provides clinical guidelines for the treatment of iron deficiency anemia during pregnancy, including oral and IV iron therapy options.
Year:
2023
Region / city:
Bristol, UK
Field:
Immunology, Autoimmune Diseases
Document Type:
Research article
Institution:
University of Bristol
Author:
Not specified
Target Audience:
Researchers in immunology, medical professionals
Period of validity:
Not specified
Approval Date:
Not specified
Date of amendments:
Not specified
Year:
2021
Region / City:
Ontario
Topic:
Aplastic Anemia Data Collection
Document Type:
Data Dictionary
Organization / Institution:
Ontario Health (Cancer Care Ontario)
Author:
Amanda Wong, Andrea Peebles, Cassandra McKay
Target Audience:
Health professionals, data managers, healthcare institutions
Period of Validity:
2021-2022
Approval Date:
May 20, 2021
Date of Changes:
May 20, 2021
Note:
Contextual Description
Year:
2022
Region / City:
Kangra, Himachal Pradesh
Subject:
Health
Document Type:
Call for Quotations
Organization / Institution:
Dr. Rajendra Prasad Government Medical College
Author:
Dr. Rashmi Kaul, Prof & Head of Dept. of Pathology
Target Audience:
Contractors, Individuals/Agencies for Research Project
Duration:
12 months
Approval Date:
19/3/2022
Amendment Date:
19/4/2022
Contextual Description:
A call for quotations for outsourcing a field investigator-cum-laboratory technician for a research project on anemia in diabetic patients at Dr. Rajendra Prasad Government Medical College.
Year:
2024
Region / city:
Not specified
Subject:
Anemia, Preoperative Care, Postoperative Outcomes, Surgery
Document type:
Research Paper
Organization / institution:
Not specified
Author:
Netz A, Hof L, Rumpf F, et al.
Target audience:
Medical professionals, Researchers
Period of validity:
Not specified
Approval date:
Not specified
Date of revisions:
Not specified
Year:
2026
Region / City:
Laboratory mouse model
Topic:
Iron metabolism and erythropoiesis
Document type:
Supplemental data / research article
Institution:
Research laboratory
Authors:
Not specified
Target audience:
Biomedical researchers
Experimental period:
Chronic dietary iron deficiency and acute erythropoietic stress experiments
Date of data collection:
Not specified
Techniques used:
qRT-PCR, Western blot, hematological analysis, flow cytometry
Animal model:
WT (IRE+/+) and Dmt1IREΔ/Δ mice
Treatments:
EPO injection, PHZ-induced hemolysis, Fe-deficient diet
Measured parameters:
Ferritin (FTH1, FTL1), FPN, HEPH expression, RBC, HBG, HCT, MCV, MCH, MCHC, RDW
Year:
2026
Field:
Genetics / Molecular Biology
Document Type:
Laboratory Exercise
Institution:
University / Educational Laboratory
Target Audience:
Undergraduate Biology Students
Learning Objectives:
Phenotypic analysis, genotypic analysis, molecular mechanisms, inheritance patterns, treatment planning
Methods:
Microscopy, DNA/RNA modeling, case study analysis
Disorder Focus:
Sickle Cell Anemia
End Product:
Lab report with drawings and answers to guided questions
Duration:
One laboratory session
Assessment:
Comparison of phenotypes, explanation of gene expression, transcription modeling
Year:
2021
Region:
Mattu Town, Oromia, Ethiopia
Topic:
Public Health / Pediatric Nutrition
Document Type:
Research Article
Institution:
Mattu University, Jimma University
Authors:
Lemi Ushu, Tilahun Yamane, Wakjira Kebede
Population:
Schoolchildren aged 7–14 years
Sample Size:
330 children
Study Design:
Cross-sectional, school-based
Methods:
Hematological analysis, parasite screening, questionnaire on sociodemographics and socioeconomic status
Key Variables:
Anemia prevalence, gender, maternal education, family income, intestinal parasitic infection, consumption of coffee or tea with meals
Data Analysis:
SPSS version 23, logistic regression
Findings:
10.4% anemia prevalence; mild 69.7%, moderate 30.3%; male gender, low maternal education, low family income, parasitic infection, coffee/tea consumption associated with anemia
Keywords:
Anemia, Associated Factors, School Children, Ethiopia
Aimed Outcome:
Identify prevalence and determinants of anemia among public schoolchildren in Mattu Town
Year:
2026
Participating countries:
Australia, Germany, South Korea, Russia, Saudi Arabia, Singapore, Sweden, Switzerland, Turkey
Document type:
Clinical trial appendix
Research centers:
Multiple international hospitals and medical universities
Study population:
Pregnant women with iron deficiency anemia
Intervention:
Ferric carboxymaltose versus oral iron
Study design:
International, open-label, randomized, controlled trial
Trial name:
FER-ASAP
Target audience:
Medical researchers, clinicians
Scope:
Multicenter, international
Language:
English
Year:
2026
Region / city:
General
Subject:
Hematology, Anemia Types
Document Type:
Medical Overview
Organization:
Healthcare Institutions
Author:
Unspecified
Target Audience:
Medical professionals, healthcare providers
Period of validity:
Ongoing
Approval Date:
Not specified
Date of changes:
Not specified
Note:
Contextual description
Year:
2019
Region / City:
UK
Topic:
Hematology, Sickle Cell Disease, Blood Transfusion
Document Type:
Guideline
Author:
Dr Elizabeth Rhodes, Dr Julia Sikorska
Target Audience:
Medical staff involved in the care of patients with Sickle Cell Disease
Period of Validity:
2019–2022
Approval Date:
14th February 2019
Review Date:
February 2022
Version:
1.0
Review date:
May 2026
Adapted from:
RDTC shared care protocol version 1.1 (October 2023, updated March 2024)
Replaces:
GMMMG Shared Care Protocols for Hydroxycarbamide in adult sickle cell disease and adult myeloproliferative disease (17/8/2017, Version 2.1)
Local approval date:
22.02.2024 (local content added)
CRG approval date:
09.04.2024
GMMMG approval date:
09.05.2024
CEGC approval date:
23.05.2024
Intended users:
NHS healthcare professionals
Target population:
Adults aged 18 and over with myeloproliferative disorders or sickle cell disease
Licensed indications:
Chronic myeloid leukaemia; Essential thrombocythaemia; Polycythaemia vera; Sickle-cell disease
Off-label indications:
Primary myelofibrosis; Unclassified myeloproliferative disorders; Psoriasis
Treatment setting:
Shared care between specialist and primary care (transfer after ≥12 weeks when stable)
Initiation responsibility:
Specialist
Prescribing transfer:
Primary care after stabilisation and satisfactory results
Dose range (initial):
Essential thrombocythaemia 15 mg/kg daily; Polycythaemia vera 15–20 mg/kg daily; Sickle-cell disease 15 mg/kg daily with 5 mg/kg steps
Maintenance dose range (sickle-cell disease):
15–30 mg/kg daily (max 35 mg/kg)
Dose adjustment considerations:
Elderly, renal impairment (CrCl ≤60 mL/min start reduced by 50%), myelotoxicity
Baseline investigations:
FBC, U&Es/eGFR or CrCl, LFTs, viral screening, lung disease screening (clinician discretion), vaccination status
Additional sickle-cell baseline:
Reticulocyte count
Monitoring frequency (primary care):
Every 8–12 weeks (FBC, U&Es, LFTs, reticulocyte count for sickle-cell disease)
Ongoing specialist monitoring:
Usually annually; specialist retains responsibility for treatment response and dose changes
Vaccination note:
Shingles vaccine eligibility for ages 50–79 (refer to Green Book)
Shared care protocol type:
Clinical prescribing and monitoring guideline
Year:
2024
Region / city:
Liverpool
Topic:
Sickle cell crisis, Aplastic crisis
Document type:
Informational leaflet
Author:
Not specified
Target audience:
Parents and carers of children with sickle cell disease
Period of validity:
Until review date
Approval date:
Not specified
Date of changes:
April 2024
Note:
Year
Topic:
Sickle Cell Anemia, Medical History, Treatment
Document Type:
Educational Activity
Year:
Not specified
Country of origin:
Surinam
Institution:
The Hemoglobin University
Authors:
Bento C; Traeger-Synodinos J; Kountouris P; et al.
Thematic area:
Hematology; Hemoglobinopathies; Molecular genetics
Document type:
Case report submission form
Gene:
HBB
Protein variant:
p.Glu7Val
cDNA variant:
c.20A>T
Variant name:
HbS
Database accession:
HbVar ID 226; IthaID 824
Phenotype:
Abnormal Doppler; organ failure due to vaso-occlusive crisis; skeletal dysplasia
Alpha genotype:
-alpha3.7/-alpha3.7
Beta genotype:
betaS/betaS
Age at evaluation:
56 years
Age at diagnosis:
2 months
Sex at birth:
Female
Family history:
Two sisters carriers of HbS
Clinical history:
Hydroxyurea treatment from childhood until 54 years; uncomplicated pregnancy at 23 years; exchange transfusion started at 54 years
Hematological parameters before transfusion:
Reported at age 53 years (Hb, MCV, MCH, RBC, Hct, Ret, RDW)
Iron status:
Ferritin 35 µg/L
Blood smear:
Target cells at normal iron indicative of alpha-thalassemia trait
Biochemical studies:
Capillary electrophoresis (Sebia); HPLC (Trinity PHR)
Molecular studies:
Sanger sequencing of exon 1 of HBB gene
Transfusion status:
Exchange transfusion from age 54 years
Year:
2026
Field:
Genetics / Molecular Biology
Document Type:
Laboratory Exercise
Institution:
University / Educational Laboratory
Target Audience:
Undergraduate Biology Students
Learning Objectives:
Phenotypic analysis, genotypic analysis, molecular mechanisms, inheritance patterns, treatment planning
Methods:
Microscopy, DNA/RNA modeling, case study analysis
Disorder Focus:
Sickle Cell Anemia
End Product:
Lab report with drawings and answers to guided questions
Duration:
One laboratory session
Assessment:
Comparison of phenotypes, explanation of gene expression, transcription modeling
Year:
2026
Organization:
Sickle Cell Society
Document Type:
Job Application Form
Position Applied For:
[To be filled by applicant]
Applicant Information:
Name, Address, Date of Birth, Contact Details
Education:
Schools, Colleges, Universities, Qualifications
Employment History:
Current and Previous Employment Details
Health Information:
Medical History, Days Absent
References:
Two Professional References Required
Declaration:
Applicant Signature and Date
Equal Opportunities Monitoring:
Sex, Ethnic Origin, Disability Status, Recruitment Source
Year:
2026
Organization:
Sickle Cell Society
Document Type:
Job Application Form
Position Applied For:
[to be filled by applicant]
Applicant Name:
[to be filled by applicant]
Date of Birth:
[to be filled by applicant]
Contact Information:
[to be filled by applicant]
Education:
[to be filled by applicant]
Employment History:
[to be filled by applicant]
Health Information:
[to be filled by applicant]
References:
[to be filled by applicant]
Declaration Date:
[to be filled by applicant]
Jurisdiction:
United Kingdom
Organisation:
Sickle Cell Society
Document Type:
Job Application Form
Confidentiality:
Confidential
Country:
United Kingdom
Related Legislation:
Asylum & Immigration Act 1996
Purpose:
Application for employment position within the organisation
Sections Included:
Personal Information; Education; Employment History; Supporting Information; Health Declaration; References; Applicant Declaration; Equal Opportunities Monitoring
Equal Opportunities Data:
Sex; Ethnic Origin; Disability Status
Medical Requirement:
Possible medical examination by an approved doctor prior to employment
Applicant Declaration:
Confirmation of truthfulness of provided information and right to work in the UK
Required Attachments:
Additional sheets for supporting information if necessary
Reference Requirement:
Two referees with professional relationship to the applicant